Takeshi Yanagishita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takeshi Yanagishita has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Watanabe
Department of Dermatology Aichi Medical University Aichi Japan
14 shared publications Yasuhiko Tamada
Department of Dermatology Aichi Medical University School of Medicine Nagakute Japan
8 shared publicationsDaisuke Watanabe
Department of Dermatology Aichi Medical University School of Medicine Nagakute Japan
7 shared publicationsYoshiyuki Kawamoto
7 shared publicationsYuichiro Ohshima
Department of Dermatology Aichi Medical University School of Medicine Nagakute Japan
7 shared publications- Masashi Kato
Department of Urology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Aichi Japan
6 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
PDF file - 32K, Transcript expression of Espin isoforms in melanocytic tumors that developed in RET-mice.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
PDF file - 32K, Transcript expression of Espin isoforms in melanocytic tumors that developed in RET-mice.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
PDF file - 138K, Specification of anti-Espin-ru antibody.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
PDF file - 138K, Specification of anti-Espin-ru antibody.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
PDF file - 44K, Gene maps of Espin isoforms.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
PDF file - 44K, Gene maps of Espin isoforms.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legend from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legend from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma
- 7 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (7) , 719-723
Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis
Head and forehead hyperhidrosis (HFH) is a disease that causes a large amount of sweating from the head region, and it significantly reduces patients' quality of life. Only a few reports have shown the effectiveness of botulinum toxin type A (BTX‐A) local injection therapy (BTX‐A therapy) for HFH. To clarify the benefits of BTX‐A for HFH, BTX‐A therapy was performed in 15 patients, and its efficacy was evaluated. The amount of sweating was measured by the ventilation capsule method and Minor's iodine‐starch test. Evaluation was also performed using the Hyperhidrosis Disease Severity Scale (HDSS) and the Dermatology Life Quality Index (DLQI). In most cases, a remarkable antiperspirant effect was observed from 2 weeks after the injection, and the effect lasted for approximately 30 weeks. HDSS and DLQI improved along with the decrease in sweating. Two patients (13.3%) complained of transient mild ptosis. There were no serious side‐effects. This study showed that BTX‐A therapy is a safe and effective treatment for HFH.
- 7 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (7) , 719-723
Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis
Head and forehead hyperhidrosis (HFH) is a disease that causes a large amount of sweating from the head region, and it significantly reduces patients' quality of life. Only a few reports have shown the effectiveness of botulinum toxin type A (BTX‐A) local injection therapy (BTX‐A therapy) for HFH. To clarify the benefits of BTX‐A for HFH, BTX‐A therapy was performed in 15 patients, and its efficacy was evaluated. The amount of sweating was measured by the ventilation capsule method and Minor's iodine‐starch test. Evaluation was also performed using the Hyperhidrosis Disease Severity Scale (HDSS) and the Dermatology Life Quality Index (DLQI). In most cases, a remarkable antiperspirant effect was observed from 2 weeks after the injection, and the effect lasted for approximately 30 weeks. HDSS and DLQI improved along with the decrease in sweating. Two patients (13.3%) complained of transient mild ptosis. There were no serious side‐effects. This study showed that BTX‐A therapy is a safe and effective treatment for HFH.
- Open Access
- 1 October 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (10) , 1482-1490
Cost-of-illness study for axillary hyperhidrosis in Japan
The prevalence of primary axillary hyperhidrosis in Japan is 5.75% (males, 6.60%; females, 4.72%) in the population aged 5-64 years. No study on comprehensively evaluated direct medical costs, hygiene product costs, and productivity loss in axillary hyperhidrosis patients has been published in Japan. The aim of this study was to estimate the cost of illness for axillary hyperhidrosis in Japan by conducting a nationwide insurance claims database analysis and a cross-sectional Web-based survey. Among patients diagnosed with primary axillary hyperhidrosis at least once between November 2012 and October 2019, health insurance receipt data of 1447 patients were analyzed. A cross-sectional Web-based survey was conducted on 321 patients aged 16-59 years with axillary hyperhidrosis to calculate hygiene product costs and productivity loss using a Work Productivity and Activity Impairment questionnaire. Furthermore, nationwide estimation was performed for the hygiene product costs and productivity loss based on the number of patients estimated from the prevalence. The annual direct medical costs per axillary hyperhidrosis patient were yen 91 491 in 2016, yen 93 155 in 2017, and yen 75 036 in 2018. In all of these years, botulinum toxin type A injection accounted for approximately 90% of the total costs. The annual total cost of hygiene products per axillary hyperhidrosis patient was yen 9325. The overall work impairment (%) of working patients with axillary hyperhidrosis was 30.52%, and its monthly productivity loss was yen 120 593/patient. The activity impairment (%) of full-time housewives with axillary hyperhidrosis was 49.05% and its monthly productivity loss was yen 176 368/patient. The annual hygiene product cost based on the nationwide estimation was yen 24.5 billion and the monthly productivity loss was yen 312 billion. The significant cost associated with axillary hyperhidrosis was clarified. If out-of-pocket expenses for treatments not covered by health insurance are included in the estimation, the cost will further increase.
- 1 October 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (10) , 1482-1490
Open AccessCost-of-illness study for axillary hyperhidrosis in Japan
The prevalence of primary axillary hyperhidrosis in Japan is 5.75% (males, 6.60%; females, 4.72%) in the population aged 5-64 years. No study on comprehensively evaluated direct medical costs, hygiene product costs, and productivity loss in axillary hyperhidrosis patients has been published in Japan. The aim of this study was to estimate the cost of illness for axillary hyperhidrosis in Japan by conducting a nationwide insurance claims database analysis and a cross-sectional Web-based survey. Among patients diagnosed with primary axillary hyperhidrosis at least once between November 2012 and October 2019, health insurance receipt data of 1447 patients were analyzed. A cross-sectional Web-based survey was conducted on 321 patients aged 16-59 years with axillary hyperhidrosis to calculate hygiene product costs and productivity loss using a Work Productivity and Activity Impairment questionnaire. Furthermore, nationwide estimation was performed for the hygiene product costs and productivity loss based on the number of patients estimated from the prevalence. The annual direct medical costs per axillary hyperhidrosis patient were yen 91 491 in 2016, yen 93 155 in 2017, and yen 75 036 in 2018. In all of these years, botulinum toxin type A injection accounted for approximately 90% of the total costs. The annual total cost of hygiene products per axillary hyperhidrosis patient was yen 9325. The overall work impairment (%) of working patients with axillary hyperhidrosis was 30.52%, and its monthly productivity loss was yen 120 593/patient. The activity impairment (%) of full-time housewives with axillary hyperhidrosis was 49.05% and its monthly productivity loss was yen 176 368/patient. The annual hygiene product cost based on the nationwide estimation was yen 24.5 billion and the monthly productivity loss was yen 312 billion. The significant cost associated with axillary hyperhidrosis was clarified. If out-of-pocket expenses for treatments not covered by health insurance are included in the estimation, the cost will further increase.
- Open Access
- 17 January 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (5) , 570-578
Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study
Background: Recent case reports have shown the efficacy of apremilast for the treatment of palmoplantar pustulosis (PPP). However, no study has statistically analyzed the clinical efficacy of oral apremilast in patients with PPP.Objectives: To evaluate the effectiveness of apremilast, a phosphodiesterase 4 inhibitor, for PPP.Materials and Methods: Among 13 patients who were diagnosed with PPP, 10 patients with PPP with either palmoplantar pustules (>1 mm diameter) or sternoclavicular joint pain were retrospectively analyzed.Results: Palmoplantar Pustulosis Area and Severity Index (mean ± SD: baseline, 13.4 ± 9.5 vs. after treatment, 5.1 ± 5.6; P = 0.013) and the number of pustules measuring > 1 mm in diameter (3.9 ± 3.9 vs. 1.3 ± 1.9; P = 0.029) significantly improved in 2 (±1) weeks. Moreover, the Dermatology Life Quality Index (9.7 ± 7.0 vs. 3.3 ± 3.6; P = 0.009) and palmoplantar itching (visual analog scale [VAS] score) (5.6 ± 3.5 vs. 2.1 ± 2.2; P = 0.026) significantly improved in 2 weeks, whereas VAS scores of palmoplantar pain (4.8 ± 4.4 vs. 1.1 ± 2.4; P = 0.081) and sternoclavicular joint pain (3.2 ± 3.8 vs. 2.0 ± 2.6; P = 0.194) did not significantly improve. Diarrhea was observed in 60.0% of our patients.Conclusion: Our study demonstrated that apremilast can effectively treat cutaneous manifestations and arthralgia in Japanese patients with PPP who had apparent pustules and/or clavicular‐sternocostal arthralgia. Owing to the retrospective design of the study and a small sample size, placebo‐controlled clinical trials with a larger number of patients are warranted to confirm the efficacy of apremilast for treatment of PPP.
- 17 January 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (5) , 570-578
Open AccessImmediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study
Background: Recent case reports have shown the efficacy of apremilast for the treatment of palmoplantar pustulosis (PPP). However, no study has statistically analyzed the clinical efficacy of oral apremilast in patients with PPP.Objectives: To evaluate the effectiveness of apremilast, a phosphodiesterase 4 inhibitor, for PPP.Materials and Methods: Among 13 patients who were diagnosed with PPP, 10 patients with PPP with either palmoplantar pustules (>1 mm diameter) or sternoclavicular joint pain were retrospectively analyzed.Results: Palmoplantar Pustulosis Area and Severity Index (mean ± SD: baseline, 13.4 ± 9.5 vs. after treatment, 5.1 ± 5.6; P = 0.013) and the number of pustules measuring > 1 mm in diameter (3.9 ± 3.9 vs. 1.3 ± 1.9; P = 0.029) significantly improved in 2 (±1) weeks. Moreover, the Dermatology Life Quality Index (9.7 ± 7.0 vs. 3.3 ± 3.6; P = 0.009) and palmoplantar itching (visual analog scale [VAS] score) (5.6 ± 3.5 vs. 2.1 ± 2.2; P = 0.026) significantly improved in 2 weeks, whereas VAS scores of palmoplantar pain (4.8 ± 4.4 vs. 1.1 ± 2.4; P = 0.081) and sternoclavicular joint pain (3.2 ± 3.8 vs. 2.0 ± 2.6; P = 0.194) did not significantly improve. Diarrhea was observed in 60.0% of our patients.Conclusion: Our study demonstrated that apremilast can effectively treat cutaneous manifestations and arthralgia in Japanese patients with PPP who had apparent pustules and/or clavicular‐sternocostal arthralgia. Owing to the retrospective design of the study and a small sample size, placebo‐controlled clinical trials with a larger number of patients are warranted to confirm the efficacy of apremilast for treatment of PPP.
- 18 March 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (5) , E211-E213
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel
- 18 March 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (5) , E211-E213
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel
- 7 November 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (1) , E6-E7
Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report
- 7 November 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (1) , E6-E7
Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report